Introduction:
Swiss antibody specialist Memo Therapeutics AG has secured CHF20m in additional funding for its Series C financing round, bringing the total amount raised to CHF45m. The funding will be used to support the clinical development of the company’s lead asset, AntiBKV, and to advance Memo Therapeutics’ pipeline by leveraging its B-cell screening platform.
- New investors Ysios Capital and Kurma Partners have joined existing investors in Memo Therapeutics’ Series C round.
- The additional funding will be used to support the clinical development of the company’s lead asset, AntiBKV, in a Phase II trial for the treatment of BK viremia in kidney transplant recipients.
- The Phase II trial will evaluate the dose and efficacy of AntiBKV and is expected to yield initial data in the first half of 2025.
- The funding will also support the development of Memo Therapeutics’ pipeline in other viral infections and oncology.
- Memo Therapeutics is developing a panel of pre-clinical assets based on its antibody discovery platform, which interrogates the antibodyomes of elite controllers of infection and cancer.
Conclusion:
Memo Therapeutics AG has secured an additional CHF20m in funding for its Series C round, bringing the total amount raised to CHF45m. The funding will support the clinical development of the company’s lead asset and the advancement of its pipeline in viral infections and oncology. This investment will enable Memo Therapeutics to further develop and strengthen its antibody discovery platform.
